COSCIENS Biopharma Completes Second Tranche of Convertible Debenture Offering
News related to:COSCIENS Biopharma Inc · 2 min read
TORONTO, ONTARIO, Sept. 16, 2026 /CourierPR/ -- COSCIENS Biopharma Inc., a biopharmaceutical company, has completed the second tranche of its non-brokered private placement of 15% unsecured convertible debentures. The company issued an additional US$4,375,000 in debentures, bringing the total amount issued in the first and second tranches to US$10,706,250. The company aims to raise up to US$20 million through this offering, with plans to close one or more additional tranches in the coming weeks.
According to the press release, the terms of the convertible debentures require shareholder approval, which will be sought through a meeting to be held within six months. The debentures and the common shares issuable upon conversion are subject to a four-month hold period under Canadian securities laws.
COSCIENS Biopharma Inc. operates through its subsidiaries, Ceapro Inc. and Nualtis™. Ceapro focuses on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources. Nualtis is a specialty pharmaceutical technology business with a focus on proprietary oral thin-film drug delivery technologies.
The company also disclosed that it agreed to pay finders’ fees of US$35,000 in the form of debentures and US$100,000 in cash for the second tranche. Any debentures issued as finders’ fees are counted towards the aggregate principal amount outstanding.
The press release notes that the completion of the second tranche is subject to customary closing conditions, and there is no assurance that additional tranches will be completed.
The company’s CEO, Peter H. Puccetti, and Chief Financial Officer, Giuliano La Fratta, are responsible for overseeing the company’s strategic plans and operations.
The company’s plans to raise capital through the convertible debenture offering reflect its ongoing efforts to support its subsidiaries’ research and development activities. Ceapro and Nualtis continue to work on developing innovative products and technologies that address unmet needs in the personal care, cosmetic, human and animal health, and pharmaceutical industries.
COSCIENS Biopharma Inc. is focused on leveraging its subsidiaries’ expertise to drive innovation and growth in the biopharmaceutical sector. The company’s strategic plans include expanding its product portfolio, enhancing its manufacturing capabilities, and exploring new market opportunities.